New antibody IMT-009 enters human trials for Hard-to-Treat cancers
Disease control
Ongoing
This early-phase trial tests a new drug called IMT-009 in about 67 people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find a safe dose, understand side effects, and see if the drug can shrink tumors. The study is o…
Phase: PHASE1, PHASE2 • Sponsor: Immunitas Therapeutics • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC